Zoetis (NYSE:ZTS) Research Coverage Started at HSBC

Equities researchers at HSBC assumed coverage on shares of Zoetis (NYSE:ZTS) in a report issued on Wednesday, FlyOnTheWall reports. The firm set a “buy” rating on the stock.

A number of other research analysts have also recently issued reports on the stock. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a report on Saturday. The Goldman Sachs Group raised their price target on shares of Zoetis from $204.00 to $213.00 and gave the stock a “buy” rating in a report on Wednesday, August 9th. Stifel Nicolaus raised their price target on shares of Zoetis from $195.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, August 28th. Finally, Piper Sandler raised their price target on shares of Zoetis from $210.00 to $220.00 and gave the stock an “overweight” rating in a report on Monday, August 14th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, Zoetis has a consensus rating of “Buy” and an average price target of $224.43.

Zoetis Price Performance

Shares of ZTS opened at $190.43 on Wednesday. The company has a market cap of $87.66 billion, a price-to-earnings ratio of 40.01, a price-to-earnings-growth ratio of 3.10 and a beta of 0.78. Zoetis has a twelve month low of $124.15 and a twelve month high of $194.99. The company has a quick ratio of 1.97, a current ratio of 3.50 and a debt-to-equity ratio of 1.42. The company has a 50 day moving average of $181.24 and a two-hundred day moving average of $174.34.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 8th. The company reported $1.41 earnings per share for the quarter, beating the consensus estimate of $1.31 by $0.10. The company had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.16 billion. Zoetis had a net margin of 26.92% and a return on equity of 52.02%. Zoetis’s revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $1.20 earnings per share. As a group, analysts predict that Zoetis will post 5.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the sale, the chief executive officer now owns 56,843 shares in the company, valued at $10,230,034.71. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $179.97, for a total transaction of $2,339,610.00. Following the sale, the chief executive officer now owns 56,843 shares in the company, valued at $10,230,034.71. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Robert J. Polzer sold 1,179 shares of the firm’s stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a total transaction of $223,939.26. Following the sale, the executive vice president now owns 2,353 shares in the company, valued at approximately $446,928.82. The disclosure for this sale can be found here. Insiders sold a total of 15,102 shares of company stock valued at $2,741,661 over the last 90 days. Insiders own 0.15% of the company’s stock.

Institutional Trading of Zoetis

Several institutional investors have recently modified their holdings of ZTS. BOS Asset Management LLC increased its holdings in shares of Zoetis by 3.2% in the 2nd quarter. BOS Asset Management LLC now owns 1,684 shares of the company’s stock valued at $290,000 after purchasing an additional 53 shares in the last quarter. Enterprise Financial Services Corp increased its holdings in shares of Zoetis by 2.3% in the 1st quarter. Enterprise Financial Services Corp now owns 2,446 shares of the company’s stock valued at $407,000 after purchasing an additional 55 shares in the last quarter. Catalyst Financial Partners LLC increased its holdings in shares of Zoetis by 3.4% in the 2nd quarter. Catalyst Financial Partners LLC now owns 1,700 shares of the company’s stock valued at $293,000 after purchasing an additional 56 shares in the last quarter. CreativeOne Wealth LLC increased its holdings in shares of Zoetis by 0.4% in the 2nd quarter. CreativeOne Wealth LLC now owns 12,833 shares of the company’s stock valued at $2,210,000 after purchasing an additional 57 shares in the last quarter. Finally, Cherry Creek Investment Advisors Inc. increased its holdings in shares of Zoetis by 1.8% in the 2nd quarter. Cherry Creek Investment Advisors Inc. now owns 3,298 shares of the company’s stock valued at $568,000 after purchasing an additional 58 shares in the last quarter. Institutional investors and hedge funds own 89.47% of the company’s stock.

About Zoetis

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.